Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-10-30
pubmed:abstractText
Agonists of the peroxisome proliferator activated receptor gamma (PPARgamma) have been shown to reduce inflammatory responses in several animal models of neurological diseases and conditions and to reduce amyloid burden in transgenic mice expressing mutant forms of human amyloid precursor protein. However, the effects of activating the related receptor PPARdelta (PPARdelta), which is expressed at higher levels in the brain than PPARgamma, on inflammation and amyloid burden have not been explored. In this study we tested the effects of the selective PPARdelta agonist GW742 in 5xFAD mice which harbor 3 mutations in amyloid precursor protein and 2 mutations in presenilin 1, develop plaques by 5-6 weeks of age, and show robust inflammation and neuronal damage. Oral delivery of GW742 significantly reduced amyloid plaque burden in the subiculum region of 3-month old male and female 5xFAD mice. GW742 also significantly reduced astrocyte activation, suggesting anti-inflammatory effects on glia cells. The changes in plaque burden were accompanied by increased expression of the amyloid degrading enzymes neprilysin and insulin degrading enzyme, while in transfected HEK293 cells, GW742 activated a neprilysin promoter driving luciferase expression. These results suggest that, as found for some PPARgamma agonists, PPARdelta agonists can also reduce amyloid burden likely to be mediated by effects on amyloid clearance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1875-5828
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
431-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19874267-Alzheimer Disease, pubmed-meshheading:19874267-Amyloid beta-Peptides, pubmed-meshheading:19874267-Amyloid beta-Protein Precursor, pubmed-meshheading:19874267-Animals, pubmed-meshheading:19874267-Astrocytes, pubmed-meshheading:19874267-Brain, pubmed-meshheading:19874267-Cell Line, pubmed-meshheading:19874267-Cells, Cultured, pubmed-meshheading:19874267-Disease Models, Animal, pubmed-meshheading:19874267-Encephalitis, pubmed-meshheading:19874267-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:19874267-Fluorescent Antibody Technique, pubmed-meshheading:19874267-Mice, pubmed-meshheading:19874267-Mice, Transgenic, pubmed-meshheading:19874267-Mutation, pubmed-meshheading:19874267-Neprilysin, pubmed-meshheading:19874267-Neurons, pubmed-meshheading:19874267-PPAR delta, pubmed-meshheading:19874267-Plaque, Amyloid, pubmed-meshheading:19874267-Presenilin-1, pubmed-meshheading:19874267-Promoter Regions, Genetic, pubmed-meshheading:19874267-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:19874267-Thiazoles, pubmed-meshheading:19874267-Transfection
pubmed:year
2009
pubmed:articleTitle
A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease.
pubmed:affiliation
Department of Anethesiology, University of Illinois, & Jesse Brown Veterans Affairs Hospital, Chicago, IL 60612, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't